Mesolon Tablet (Methylprednisolone)

Adult use

The initial dose may vary from 4mg to 48mg per day as methylprednisolone, depending on the symptoms of the specific disease. A low dose is generally sufficient for conditions that are not severe, but a high initial dose may be required in certain patients. The initial dose should be maintained or adjusted until a satisfactory response is achieved. If there is no satisfactory clinical outcome after a reasonable period, discontinue treatment and switch to another appropriate therapy. The dose should be determined individually according to the various diseases being treated and the patient's response. After an adequate response is achieved, determine an appropriate maintenance dose by reducing the initial dose at suitable intervals until the lowest dose that maintains an adequate clinical response is reached. Continuous monitoring of the dose is required. Situations that may require dose adjustment include improvement or worsening of the disease, individual patient response to the medication, and the effect on the patient of exposure to stressful circumstances that are not directly related to the symptoms of the disease being treated. In the latter case, it may be necessary to increase the dose for a period sufficient to achieve satisfactory control of the patient's condition. After long-term treatment, gradual dose reduction is recommended when discontinuing the medication. Multiple sclerosis For treatment of acute exacerbations of multiple sclerosis, administration of prednisolone 200mg daily for 1 week followed by prednisolone 80mg every other day for 1 month is effective (methylprednisolone 4mg is equivalent to prednisolone 5mg). ADT (Alternate Day Therapy) Alternate-day therapy is a regimen in which twice the daily dose is given in the morning on one of every two days. Although a single morning dose causes considerably less adrenal suppression than taking prednisolone (10mg) in four divided doses every 6 hours, there is evidence that, when pharmacologic doses are used, a slight suppressive effect on adrenal activity continues into the following day. In addition, a single dose of any corticosteroid has been shown to suppress the adrenal cortex for up to 2 days or more. Other corticosteroids, including methylprednisolone, hydrocortisone, prednisone, and prednisolone, are considered short-acting (one dose causes adrenocortical suppression for 1¼ to 1½ days), and therefore alternate-day therapy is recommended. The initial suppressive dose should be continued until a satisfactory clinical response is obtained, usually for 4 to 10 days in many allergic and collagen diseases. ① Switch to ADT and gradually reduce the amount of corticosteroid given every other day. ② Reduce the daily corticosteroid dose to the minimum effective dose as soon as possible, depending on control of disease progression, and then switch to an alternate-day schedule. If this is difficult, it is preferable to administer 3 or even 4 times the daily dose every other day rather than merely twice the daily dose. Once the patient is controlled again, try to reduce this dose to the minimum. Adrenocortical activity is at its maximum from 2 a.m. to 8 a.m. and at its minimum from 4 p.m. to midnight. When administered during the period of maximum activity (in the morning), exogenous corticosteroids suppress adrenocortical activity the least. If an acute exacerbation occurs during disease progression, it may be necessary to return to a dose of corticosteroid divided throughout the day that provides complete suppression for control. Once control is achieved, the established alternate-day regimen may be tried again.

This medication must not be administered to certain patients. For instance, it should not be used in individuals with allergies to this drug or its components, infections without appropriate antimicrobial therapy, or systemic fungal infections, as it may worsen infections. It should also not be given to patients with herpes simplex, herpes zoster, or chickenpox, or those receiving live vaccines. It contains lactose, so patients with lactose intolerance or genetic metabolic disorders must also exercise caution. This medication should be used cautiously in some patients. Special care is needed in patients with glaucoma, tuberculosis, keratitis, cataracts, electrolyte abnormalities, hypertension, thrombosis, and recent bowel anastomosis, as it may aggravate Symptoms. Patients with diabetes, osteoporosis, renal failure, heart failure, hypothyroidism, fatty liver, severe myasthenia gravis, elderly individuals, epilepsy, and ulcerative colitis should also receive cautious treatment. This medication can cause various side effects, so symptoms should be carefully monitored during use. Potential effects include fluid and electrolyte disturbances such as edema, sodium retention, potassium loss, muscle weakness, osteoporosis, arthralgia, skin changes, gastrointestinal abnormalities, and neuropsychiatric symptoms. Abnormalities of the endocrine system, increased intraocular pressure or glaucoma, and adverse immune reactions have also been reported. Prolonged use may result in adrenal insufficiency, and discontinuing the medication suddenly may cause severe withdrawal symptoms, so it should be reduced gradually. There may be increased susceptibility to infections, so during immunosuppressed states, care should be taken to avoid exposure to chickenpox or measles, with vaccinations also being restricted. This medication can interact with various other drugs, so consultation with a healthcare professional is required when used in conjunction with other medications. Special care is necessary when used with drugs that may cause cardiac arrhythmias, anticoagulants, hypoglycemic agents, and diuretics, as dosage adjustments and monitoring will be needed. During pregnancy, this medication may harm the fetus, so it should only be used when strictly necessary, and breastfeeding should be avoided as the drug may pass into breast milk. In pediatric use, growth retardation may occur, so it should be administered cautiously at the minimum effective dose, and growth status should be monitored. Elderly patients are also at increased risk of side effects, requiring extra caution. When using this medication, it is essential to fully understand these precautions and potential side effects, and to take the drug safely according to medical advice.

Edema, sodium retention, potassium loss, fluid retention, hypokalemic metabolic alkalosis, congestive heart failure, hypertension, myasthenia, avascular necrosis of the femoral and humeral heads, steroid myopathy, loss of muscle mass, pathologic fractures of the iliac bone, osteoporosis, vertebral compression fractures, arthralgia, tendon rupture, increased ALT, increased AST, increased ALP, nausea, thirst, vomiting, stomach pain, loss of appetite, increased appetite, peptic ulcer, abdominal distension, pancreatitis, esophagitis ulcerosa, diarrhea, delayed wound healing, facial erythema, thin and fragile skin, abnormal sweating, petechiae, purpura, suppression of skin reactions, purpura, acne, hirsutism, alopecia, pigmentation, papilledema, increased intracranial pressure, convulsions, dizziness, headache, insomnia, euphoria, depression, Cushing's syndrome, menstrual irregularities, growth inhibition in children, symptoms of latent diabetes mellitus, secondary adrenal insufficiency, pituitary apoplexy, impaired glucose tolerance, increased requirement for insulin or oral hypoglycemic agents, suppression of adrenocorticotropic hormone secretion, increased intraocular pressure, glaucoma, subcapsular cataract, secondary eye infections, central serous chorioretinopathy, retinal disorders, exophthalmos, negative nitrogen balance, immune system disorders, allergic reactions, shock, urticaria, anaphylactic reactions, hypersensitivity reactions

This medication can be sensitive to air and moisture, so it should be stored in a tightly sealed container. A storage temperature of 1 to 30 degrees Celsius is recommended. This ensures that the drug's effectiveness is well maintained and that it is safe for use.

Appearance

White round tablet

Package unit

30 tablets/bottle, 300 tablets/bottle